




# FFPE Multi-Omics for Clinical Oncology

Optimize **patient selection precision** & **trial success**.



Clinical oncology programs require robust biomarkers for patient stratification, target engagement, and PK/PD data to guide enrollment, dosing, and patient response. Analysis of **FFPE trial samples is traditionally limited** to single-plex immunohistochemistry (IHC) or genomic sequencing, resulting in:

**Limited protein-level measure** of target expression and tissue PK/PD modulation.

**Slow identification** of target engagement and patient responders.

**The result? Slower trials, non-optimized dosing, and missed responder subgroups.**

Sapient's **FFPE Multi-Omics Platform** unlocks **actionable drug effect insights** in archival tissue for **smarter trials**.

Sapient's next-generation mass spectrometry-based FFPE proteomics method delivers **deep, quantitative proteomic data** via the direct measure of >10,000 proteins in FFPE tissue. **Targeted, quantitative assays can be optimized to evaluate key protein targets** within clinical FFPE samples with exceptional reproducibility (inter-section CV < 8%).

**Sapient's DynamiQ™ virtual biobank** offers streamlined access to thousands of annotated FFPE tumors and tissues, enabling clinical teams to perform retrospective validation **without new collections**, accelerating biomarker qualification.

- ✓ **Targeted, quantitative protein assays** including for phospho- and glyco-proteins
- ✓ Measures across **200+ oncogenes, 500+ approved drug targets, and 100+ pathways**
- ✓ Quantitative measure of **drug tissue distribution**
- ✓ **Streamlined access to FFPE samples** via Sapient's DynamiQ virtual biobank


# Multi-omic molecular mapping

Our FFPE proteomics **seamlessly integrates** with other omics offerings available through Sapient, including:



## FFPE proteomics

for protein  
expression and  
pathway activity



## FFPE DNA

**sequencing**  
for mutation and  
CNV mapping



## Single-cell

**sequencing**  
for cell-type  
specific expression



## Spatial

**profiling**  
for tissue  
contextualization

Designed to **accelerate oncology trials**, Sapient's FFPE Multi-Omics Platform provides **comprehensive molecular views of tumor pathology, drug effect, and patient response.**

Typical Bottleneck	Sapient Solution	Program Impact
Limited multiplex capability	Deep proteomics on trial FFPE samples	<b>Multiplexed biomarker discovery</b>
Slow responder analysis	Comprehensive evaluation of TE and drug tissue distribution	<b>Capture drug effects in early clinical studies</b>
Fragmented molecular data	Unified proteogenomic output	<b>Map tumor biology from mutation to pathway activation to spatial localization</b>

## Reduce delays, optimize dosing, and identify responders early.

Through deep, quantitative profiling, Sapient's FFPE proteomics enables **early detection of pathway modulation and target engagement** to improve patient stratification and guide dose adjustments in early clinical phases.

- Enables **rapid re-analysis of archived trial biopsies** to identify biomarkers, responder groups, and drug mechanism of action
- Optimized for clinical programs with **hundreds to thousands of FFPE samples with rapid turnaround**
- Support for **clinical biomarker confirmation/verification**

Transform FFPE tissue into an **engine for actionable clinical intelligence**, from target engagement to responder analysis, with Sapient's FFPE Multi-Omics Platform.

**For prioritized access opportunities, contact [discover@sapient.bio](mailto:discover@sapient.bio).**